PMHNP Scope of Practice for Anxiety in North Carolina

If you’re a psychiatrist or PMHNP treating anxiety via telehealth, you’re probably tired of piecing together contradictory information about what you can actually prescribe and where. Can you start a patient on Xanax after a video visit? Does your state require an in-person exam first? What about that DEA rule everyone keeps mentioning?

Here’s the reality: as of February 2026, federal rules still allow you to prescribe controlled anxiety medications via telehealth without an in-person visit — but that’s a temporary extension that could change. Meanwhile, each state has its own prescribing laws that layer on top of federal regulations, creating a compliance puzzle that can make or break your telehealth practice.

This guide cuts through the noise. We’ll walk through what’s actually required for prescribing anxiety medications via telehealth, how it differs by state, and what psychiatrists versus PMHNPs need to know about their scope of practice.

Federal DEA Rules: The Temporary Lifeline for Telehealth Prescribing

Let’s start with the federal baseline. Under normal circumstances, the Ryan Haight Act (21 U.S.C. §829(e)) requires an in-person medical evaluation before a provider can prescribe any controlled substance ‘by means of the Internet.’ For anxiety treatment, this mainly affects benzodiazepines (Schedule IV) like alprazolam (Xanax), clonazepam (Klonopin), and lorazepam (Ativan).

But here’s what changed during COVID — and what’s still in effect today:

In March 2020, the DEA invoked public health emergency exceptions that allowed providers to prescribe controlled substances via telehealth without a prior in-person exam. This flexibility has been extended multiple times. Most recently, in November 2024, the DEA extended these telemedicine prescribing rules through December 31, 2025.

What this means practically: You can currently evaluate a new anxiety patient via video visit and prescribe benzodiazepines on that same call, no in-person visit required. This applies to Schedule II–V controlled substances, as long as you:

• Conduct an appropriate evaluation via live audio-video
• Hold a valid DEA registration
• Comply with all state laws and documentation requirements
• Follow standard of care for prescribing

The uncertainty: In 2023, the DEA proposed new rules that would have reinstated in-person visit requirements for controlled substance prescribing. After receiving over 38,000 public comments (many from mental health providers), the DEA postponed those restrictions and is now working on a ‘new path forward for telemedicine.’

Translation: Expect potential rule changes in late 2025 or 2026. The DEA might introduce a hybrid model — perhaps allowing an initial benzodiazepine prescription via telehealth but requiring an in-person assessment within 30 days to continue. Or they might finally implement the ‘special telemedicine registration’ mentioned in the Ryan Haight Act but never actually created.

For now, anxiety prescribers should:

• Stay current with DEA announcements
• Document telehealth encounters thoroughly
• Have contingency plans (like affiliate clinic partnerships) if in-person requirements return
• Consider practice patterns that balance access with potential regulatory shifts

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist Scope of Practice: The Full Autonomy Advantage

If you’re a psychiatrist (MD or DO), your scope of practice for anxiety treatment is straightforward: you can do everything.

Every state authorizes licensed physicians to:

• Independently diagnose any anxiety disorder
• Provide psychotherapy and counseling
• Prescribe any medication for anxiety, from SSRIs to Schedule II controlled substances
• Make all treatment decisions without supervision or collaborative agreements

You don’t need physician oversight. You don’t need protocols. You don’t need anyone’s approval to prescribe.

The regulatory challenges for psychiatrists aren’t about scope limitations — they’re about compliance with prescribing regulations:

State PDMP Requirements

Almost every state now mandates checking the Prescription Drug Monitoring Program before prescribing controlled substances. Key state requirements:

• New York: Must check the I-STOP PMP registry before every Schedule II–IV prescription (including all benzodiazepines)
• Florida: PDMP check required before prescribing any Schedule II–V controlled substance and at least every 90 days for ongoing therapy
• Pennsylvania: Must check PA PDMP before each prescription of benzodiazepines or opioids — this includes refills, not just new prescriptions
• California: Must query CURES database at least every 4 months for ongoing Schedule II–IV prescriptions
• Texas: Mandatory PDMP check for opioids, benzodiazepines, barbiturates, and carisoprodol before prescribing
• Illinois: Required to check IL PMP for Schedule II narcotics; strongly encouraged for all controlled substances

Most EHR systems now integrate PDMP queries, but you need to build this into your workflow. State boards audit prescribers for PDMP compliance.

E-Prescribing Mandates

Several states require electronic prescribing for controlled substances:

• New York and California: Mandatory e-prescribing for all medications (controlled and non-controlled)
• Pennsylvania: E-prescribing required for controlled substances with limited exceptions
• Florida: Effectively requires e-prescribing for controlled substances (paper requires special counterfeit-proof pads)

You’ll need a DEA-compliant EPCS system with two-factor authentication. Most telehealth platforms provide this, but verify before joining.

Multi-State Licensing

Here’s the catch with telehealth: you must be licensed in every state where your patients are located. Treating a California patient from your New York office without a California license is illegal, even via video.

Your options:

• Interstate Medical Licensure Compact (IMLC): Streamlines licensing across 40 member states (includes TX, FL, PA, IL — but not CA or NY)
• Individual state licensure: Required for California and New York
• Some platforms (like Klarity) assist with multi-state licensing processes

Bottom line for psychiatrists: Your scope is unrestricted, but administrative compliance is critical. The business advantage? You can independently make all treatment decisions, evaluate complex cases, and prescribe the full range of anxiety medications — which is exactly what patients seeking telehealth care need.

PMHNP Scope of Practice: State-by-State Variation That Actually Matters

If you’re a Psychiatric Mental Health Nurse Practitioner, you can diagnose and treat anxiety disorders in every state. But how independently you can practice — and what you can prescribe — varies dramatically.

Practice Authority: The Independence Spectrum

Full Practice Authority States (for experienced PMHNPs):

• Illinois: NPs with 4,000+ clinical hours can apply for Full Practice Authority and practice independently, including prescribing
• New York: NPs with 3,600+ hours of physician-supervised practice can practice independently (law enacted 2022)
• California: AB 890 created a pathway to independence for NPs with ≥3 years experience (full independence across all settings by January 2026)

In these states, an experienced PMHNP can evaluate anxiety patients, diagnose, prescribe medications, and manage treatment completely independently — no physician collaboration required.

Restricted Practice States (physician oversight required):

• Texas: Must have a Prescriptive Authority Agreement (PAA) with a supervising physician; one physician can supervise maximum 7 NPs
• Florida: Must practice under a supervisory protocol with a physician (psychiatric NPs are not included in FL’s autonomous NP category)
• Pennsylvania: Requires written collaborative agreement with a physician; no limit on number of NPs per physician currently

In these states, you need a formal agreement with a physician outlining your scope, prescribing authority, and consultation requirements. The physician doesn’t need to be on-site for telehealth, but the legal relationship must exist.

What this means for telehealth platforms: Klarity and similar services must ensure physician collaborators are available in restricted states. In independent states, experienced PMHNPs can be deployed more flexibly.

Controlled Substance Prescribing: The Real Complexity

Every state allows PMHNPs with prescriptive authority to prescribe non-controlled anxiety medications (SSRIs, SNRIs, buspirone). Controlled substances are where things get complicated.

Schedule II Restrictions

Many states limit or prohibit NP prescribing of Schedule II substances (mainly relevant for ADHD medications often prescribed alongside anxiety treatment):

Texas: APRNs cannot prescribe Schedule II drugs in outpatient settings except in hospitals, emergency departments, or hospice/palliative care for terminal patients. Period. If you’re a Texas PMHNP treating a patient with comorbid ADHD and anxiety via telehealth, you cannot prescribe their Adderall — the supervising physician must do it.

Florida: NPs can prescribe Schedule II for maximum 7-day supply unless the NP is a certified ‘psychiatric nurse’ treating mental illness — in which case the limit doesn’t apply. This carve-out allows PMHNPs more flexibility for psychiatric medications.

Pennsylvania: NPs can prescribe Schedule II for up to 30-day supply under collaborative agreement (must notify physician within 24 hours)

Illinois: NPs with Full Practice Authority can prescribe Schedule II but must have a physician consultation relationship available for the first 5 years when prescribing Schedule II opioids (non-narcotic Schedule IIs like stimulants don’t require this)

Schedule III-V (Benzodiazepines)

Most anxiety medications are Schedule IV benzodiazepines. All states permit NPs to prescribe these, with variations:

• Pennsylvania: Schedule III–IV prescriptions limited to 90-day supply per prescription under collaborative agreement
• Florida: No specific quantity limits for psychiatric NPs prescribing Schedule IV anxiolytics (but must be in collaborative protocol)
• Other states: Generally allow benzodiazepine prescribing as long as NP has prescriptive authority

Additional State Requirements for NPs

Beyond practice authority and prescribing limits:

• State Controlled Substance License: Illinois and Florida require separate state controlled substance permits (in addition to DEA registration)
• Continuing Education: Florida mandates a 3-hour CE course on safe controlled substance prescribing
• PDMP Requirements: Same as physicians in each state (see above)
• E-Prescribing: Same mandates as physicians

Bottom line for PMHNPs: Know your state’s specific rules. An experienced PMHNP in New York has nearly identical autonomy to a psychiatrist. A PMHNP in Texas needs physician backup for Schedule II prescriptions and operates under supervision. These aren’t minor differences — they fundamentally affect how you practice and what platforms you can work with.

State-Specific Telehealth Prescribing Rules

Federal DEA rules set the controlled substance baseline, but each state adds its own telehealth requirements. Here’s what matters for the six highest-population states:

California

What’s allowed: No state-mandated in-person exam before prescribing via telehealth. An ‘appropriate prior examination’ can be conducted entirely via telehealth (even asynchronous methods like detailed questionnaires, if clinically adequate).

Controlled substances: No state restrictions beyond federal law. Can prescribe benzodiazepines via telehealth.

Key requirements:

• E-prescribing required for all prescriptions (since 2022)
• Must check CURES PDMP at least every 4 months for Schedule II–IV controlled substances
• Must have California license (state not in IMLC — no shortcuts)

NP update: AB 890 phased in NP independence; by January 2026, experienced NPs can practice fully independently.

Practical note: California supports tele-mental health broadly. Medical Board guidance treats telehealth as equivalent to in-person care if standard of care is met.

Texas

What’s allowed: Telemedicine permitted if practitioner establishes valid relationship via synchronous audio-visual interaction (video required for new patients).

Controlled substances: Can prescribe via telehealth except for chronic pain management (Schedule II for chronic pain requires in-person exam). Mental health use of controlled medications is exempt from pain management restrictions.

Key requirements:

• Mandatory PDMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• Must use real-time video for initial evaluation
• Texas license required (state is in IMLC for physicians)

NP restrictions: APRNs require physician PAA and cannot prescribe Schedule II in outpatient settings (except hospital/hospice).

Practical note: Texas was early to modernize telemedicine (2017’s SB 1107 removed old in-person requirements), but NP restrictions remain tight.

Florida

What’s allowed: Explicit telehealth statute with unique controlled substance rules.

Controlled substances: Schedule II prescribing via telehealth is prohibited EXCEPT for:

• Treatment of psychiatric disorders
• Inpatient hospital care
• Hospice care
• Nursing home residents

This carve-out means psychiatrists and PMHNPs can prescribe Schedule II psychiatric medications (like stimulants for ADHD) via telehealth, but other providers cannot use telehealth for Schedule II.

Key requirements:

• Must obtain written patient consent for telehealth services
• PDMP (E-FORCSE) check required before any Schedule II–V prescription and every 90 days
• E-prescribing effectively mandatory for controlled substances
• Florida license OR out-of-state Telehealth Provider Registration (unique to FL — allows limited practice without full license)

NP restrictions: PMHNPs must have physician supervisory protocol. Certified psychiatric NPs exempt from 7-day Schedule II limit when treating mental illness.

Practical note: Florida’s telehealth registration for out-of-state providers is rare nationally and can ease multi-state practice, but psychiatric NPs still need physician collaboration.

New York

What’s allowed: Telehealth permitted for psychiatric evaluation and treatment with no state-mandated in-person exam.

Controlled substances: No state prohibitions beyond federal law. Relies on DEA rules (currently allowing controlled prescribing via telehealth under COVID extensions).

Key requirements:

• Mandatory I-STOP PDMP check before every Schedule II–IV prescription (most stringent PDMP requirement nationally)
• E-prescribing required for all medications (since 2016)
• NY license required (state not in IMLC)

NP update: Full practice authority for NPs with 3,600+ hours (law made permanent in 2022). Experienced PMHNPs can practice independently.

Practical note: NYC has massive telepsychiatry adoption. State emphasizes standard of care and confidentiality but is otherwise permissive for mental health telehealth.

Pennsylvania

What’s allowed: Telemedicine permitted if standard of care is met. No comprehensive statute until insurance law passed in 2024, but Medical Board allows telehealth prescribing with equivalent evaluation to in-person.

Controlled substances: No state bans on telehealth prescribing. Follows federal DEA rules.

Key requirements:

• Must check PA PDMP before each prescription of benzodiazepines or opioids (including refills, not just initial prescriptions — strictest interpretation)
• E-prescribing mandatory for controlled substances (since 2019)
• PA license required (state is in IMLC for physicians)

NP restrictions: Collaborative agreement required. Schedule II limited to 30-day supply, Schedule III–IV to 90-day supply per prescription.

Practical note: PA boards expect video for new evaluations (audio-only should be rare and documented). State introduced multiple NP independence bills but none have passed as of 2025.

Illinois

What’s allowed: Telehealth encouraged with no in-person exam requirement. State law explicitly permits audio-only telehealth for mental health services if necessary.

Controlled substances: No state telehealth restrictions. Default to federal rules.

Key requirements:

• Must register with and consult Illinois PMP for all Schedule II prescriptions
• State controlled substance license required (in addition to DEA)
• IL license required (physicians can use IMLC; nurses joined NLC for RNs in 2022 but APRNs need IL-specific license)

NP advantage: Full Practice Authority available after 4,000 hours. FPA NPs can prescribe independently (with physician consult relationship for Schedule II opioids first 5 years).

Practical note: Illinois was early to allow audio-only for behavioral health — useful for patients without video access, though video still recommended for thorough mental status exams.

Quick Reference: State Requirements for Anxiety Prescribers

What This Means for Your Practice

If You’re a Psychiatrist

Your advantages:

• Full independent practice authority in every state
• Can prescribe the complete range of anxiety medications
• No formulary restrictions or supervision requirements

Your compliance responsibilities:

• Multi-state licensure (use IMLC where available)
• PDMP checks per state requirements (some states require checks on every prescription)
• E-prescribing systems with EPCS compliance
• Stay current with DEA rule changes on telehealth controlled substance prescribing

Economic reality: The platform model (like Klarity) makes sense because patient acquisition through traditional channels (SEO, Google Ads, directories) costs $200-500+ per qualified psychiatric patient when you factor in agency fees, ad testing, staff time to qualify leads, no-show rates, and months of SEO investment before results.

Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, you pay a standard fee per booked patient. Pre-qualified patients matched to your availability. No wasted ad spend. Built-in telehealth infrastructure. Both insurance and cash-pay flow. You only pay when you see patients — guaranteed ROI vs marketing risk.

If You’re a PMHNP

Your advantages:

• Growing independence (over half of states now have full or reduced practice restrictions)
• Can diagnose and treat full range of anxiety disorders
• Telehealth platforms actively recruiting PMHNPs to address provider shortage

Your state-specific considerations:

• Full practice states (IL, NY, CA by 2026): Similar autonomy to psychiatrists for experienced NPs
• Restricted states (TX, FL, PA): Need physician collaboration; platform must provide this support
• Schedule II restrictions: Know your state’s limits (especially relevant for comorbid ADHD)

Platform value: In restricted states, telehealth companies handle physician collaboration infrastructure. In independent states, you avoid the overhead of finding and maintaining collaboration agreements yourself. Either way, the platform removes patient acquisition costs and compliance complexity.

The Regulatory Landscape Is Still Shifting

Here’s what to watch:

DEA rules (expected late 2025/early 2026):

• Potential reinstatement of in-person exam requirements for controlled substance prescribing
• Possible introduction of special telemedicine DEA registration
• Likely hybrid models allowing limited telehealth prescribing with periodic in-person assessments

State trends:

• More states moving toward NP full practice authority (addressing provider shortage)
• Stricter PDMP requirements (Pennsylvania’s ‘every prescription’ model may spread)
• Increased telehealth regulation clarity (most states still have patchwork rules from COVID emergency orders)

What providers should do now:

• Build documentation habits that would satisfy stricter standards (thorough telehealth notes, mental status exams, rationale for controlled substance prescriptions)
• Consider hybrid practice models that include some in-person capacity or clinic partnerships
• Stay connected with professional organizations tracking regulatory changes
• Work with platforms or systems that monitor compliance across states

Why This Matters for Joining a Platform Like Klarity

Understanding these regulations isn’t just about compliance — it’s about understanding the value proposition of a telehealth platform versus going solo.

DIY marketing reality:

• SEO takes 6-12 months of consistent investment before meaningful patient flow
• Google Ads for mental health keywords run $15-40+ per click (most don’t convert)
• Realistic cost per booked patient through PPC: $200-400+
• Psychology Today charges monthly fees AND you compete with hundreds of providers on the same page
• Total monthly marketing spend for meaningful patient volume: $3,000-5,000+ with uncertain results

Platform model:

• Pay-per-appointment (no upfront marketing spend)
• Pre-qualified patients already matched to your specialty
• Built-in telehealth infrastructure (no separate platform costs)
• Multi-state licensing support
• Compliance infrastructure for state-specific requirements (physician collaboration in restricted states, PDMP integration, e-prescribing)
• Both insurance and cash-pay patient flow
• You control your schedule

The economic choice: Instead of spending thousands monthly on marketing with no guarantee of ROI, you pay only when a qualified patient books with you. The platform removes patient acquisition risk entirely — especially valuable for providers starting out or scaling to new states.

Next Steps

The regulatory landscape for telehealth anxiety treatment is complex but navigable. Whether you’re a psychiatrist with full prescribing autonomy or a PMHNP working within state-specific scope, the key is understanding:

1. Federal DEA rules (currently permissive through Dec 2025, likely to change)
2. Your state’s specific requirements (PDMP checks, e-prescribing, practice authority)
3. Your scope of practice (independent vs collaborative, prescribing limits)
4. The business model that removes patient acquisition risk

If you’re ready to treat anxiety patients via telehealth without the compliance headaches and marketing gamble, platforms like Klarity handle the infrastructure while you focus on clinical care.

Explore Klarity’s provider network to see how we support psychiatrists and PMHNPs across multiple states with built-in compliance, patient matching, and a pay-per-appointment model that guarantees ROI.

Frequently Asked Questions

Can I prescribe benzodiazepines via telehealth in 2025?

Yes, currently. Federal DEA rules allow prescribing Schedule II–V controlled substances (including benzodiazepines) via telehealth through December 31, 2025, without requiring an in-person exam. You must conduct an appropriate evaluation via audio-video and comply with state laws. This is a temporary extension — future DEA rules may reinstate in-person requirements.

Do I need a separate license for each state where I see telehealth patients?

Yes. You must be licensed in the state where the patient is physically located during the telehealth visit. Options include individual state licenses, using the Interstate Medical Licensure Compact (IMLC) for physicians, or in Florida’s case, registering as an out-of-state telehealth provider. No federal telehealth license exists.

What’s the difference between psychiatrist and PMHNP scope for anxiety treatment?

Psychiatrists have full independent practice authority in all states — no supervision required, can prescribe any medication including all controlled substances. PMHNPs can diagnose and treat anxiety in every state but face varying restrictions: some states allow full independence (IL, NY, CA by 2026), others require physician collaboration (TX, FL, PA). Many states also restrict NP prescribing of Schedule II medications.

How often do I need to check the prescription monitoring program?

It varies by state. New York requires checking before every Schedule II–IV prescription. Pennsylvania requires checking before each benzodiazepine or opioid prescription (including refills). Florida and California require checks every 90 days and 4 months respectively for ongoing therapy. Texas requires checking before initial prescriptions of certain controlled substances. Check your specific state requirements.

Can PMHNPs prescribe anxiety medications independently?

Depends on the state. PMHNPs with Full Practice Authority in Illinois, New York (after 3,600 hours), and California (by 2026) can prescribe independently. In Texas, Florida, and Pennsylvania, PMHNPs need physician collaborative agreements. All PMHNPs can prescribe non-controlled anxiety medications (SSRIs, SNRIs). Benzodiazepine prescribing (Schedule IV) is generally allowed but must follow state practice authority rules.

What happens if DEA rules change in 2026?

The DEA is developing new telemedicine prescribing regulations that may require in-person exams for controlled substance prescriptions. Likely scenarios include: mandatory in-person visit before prescribing, 30-day supply limits for telehealth-only prescriptions, or special DEA telemedicine registration requirements. Providers should prepare for hybrid models that include some in-person capacity or clinic partnerships.

Citations & Sources

1. DEA & HHS. (November 15, 2024). ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Drug Enforcement Administration. https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. 21 U.S.C. § 829(e) and § 802(54) – Ryan Haight Online Pharmacy Consumer Protection Act. Cornell Law School Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/829

3. Center for Connected Health Policy. (Updated January 9, 2026). ‘State Telehealth Policies: Online Prescribing.’ https://www.cchpca.org/topic/online-prescribing/

4. Florida Statutes §456.47 (Telehealth Services) and §464.012 (Advanced Practice Registered Nurses). 2025 Florida Statutes. http://www.leg.state.fl.us/Statutes/

5. Texas Board of Nursing. (Updated December 9, 2025). ‘APRN Prescriptive Authority FAQ – Schedule II Prescribing.’ https://www.bon.texas.gov/faqpracticeaprn.asp.html

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94